A method and system for assisting management of pregnancy risks based on cardiovascular disease

Abstract

The present invention provides a method and system for auxiliary management of pregnancy risks based on cardiovascular diseases, relating to the technical field of medical auxiliary management. The pregnancy risk auxiliary management system of the present invention includes a system management module, an assessment module, a follow-up management module, an information interaction module and a supporting database. The auxiliary management system can automatically generate targeted pregnancy risk assessment results and follow-up management suggestions based on the patient's relevant basic data, thereby not only significantly improving the efficiency of physicians and pharmacists in assessing and managing the cardiovascular risks of patients receiving ART, greatly saving follow-up management time; but also significantly improving the accuracy, comprehensiveness and reliability of follow-up management suggestions, helping to provide more timely and effective follow-up management suggestions for related cardiovascular disease risks during pregnancy, and is suitable for large-scale application in auxiliary management of pregnancy risks based on cardiovascular diseases.

Description

Technical Field

[0001] The present invention relates to the field of medical technology, in particular to the field of medical assistance technology, and in particular to a method and system for assisting management of pregnancy risks based on cardiovascular disease. Background Art

[0002] Assisted reproductive technology (ART) refers to the use of medically assisted means to help infertile couples conceive. It primarily includes artificial insemination, in vitro fertilization-embryo transfer, and its derivatives, such as intracytoplasmic sperm injection (ICSI) and preimplantation genetic testing (PGT). Since the birth of the first in vitro fertilization (IVF) baby in 1978, ART has continued to develop and has become an important treatment for infertility.

[0003] In recent years, with the increasing use of artificial insemination techniques (ART), a growing body of research has focused on the potential link between assisted reproductive technology (ART) and cardiovascular disease (CVD). Some studies suggest that individuals conceived through ART may be at increased risk for CVD. During ART, certain regimens that increase exogenous estrogen levels may induce a prothrombotic state, disrupting the renin-angiotensin-aldosterone system, potentially leading to endothelial damage and increasing the risk of pregnancy-induced hypertension.

[0004] With the continuous improvement of medical standards, more and more patients with cardiovascular disease or CVD risk factors are using or considering ART technology. However, although ART is well tolerated in most people, it is poorly tolerated in CVD patients, which may be related to the cardiovascular health status of CVD patients themselves.

[0005] Currently, there is limited information available on the assessment and management of cardiovascular disease risks after ART, as well as the risks of pregnancy in patients with cardiovascular disease undergoing ART. This leaves both physicians and patients facing significant uncertainty during pregnancy after ART, making it difficult to accurately assess and manage cardiovascular disease risk. Therefore, it is urgent to design a method and system for assessing and managing cardiovascular risk in patients undergoing assisted reproductive technology. Summary of the Invention

[0006] The purpose of the present invention is to overcome the problem that the existing technology is difficult to accurately assess and control the pregnancy risks based on cardiovascular diseases, and to provide a method and system for auxiliary management of pregnancy risks based on cardiovascular diseases.

[0007] In order to achieve the above-mentioned purpose of the invention, the present invention provides a pregnancy risk auxiliary management system based on cardiovascular disease, which includes a system management module, an evaluation module, a follow-up management module, an information interaction module and a support database;

[0008] Wherein, the system management module is used to assist in the basic maintenance and setting of the management system;

[0009] The assessment module is used to assess the patient's pregnancy risk based on the patient-related basic data collected by the patient information interaction module, and output the pregnancy risk assessment result and a recommendation on whether to continue ART; the patient-related basic data includes at least one of basic information, liver and kidney function level, pregnancy symptoms and signs, and diagnosis and treatment plan;

[0010] The follow-up management module is used to output follow-up management suggestions based on the patient's relevant basic data and pregnancy risk assessment results;

[0011] The information interaction module includes a patient information interaction module and a physician information interaction module;

[0012] The patient information interaction module is used to input patient-related basic data and receive the pregnancy risk assessment results output by the assessment module, the recommendation on whether to continue ART, and the follow-up management recommendations output by the follow-up management module;

[0013] The physician information interaction module is used to receive and review the pregnancy risk assessment results output by the assessment module, the recommendation on whether to continue ART, and the follow-up management recommendations output by the follow-up management module;

[0014] The supporting database is used to provide data support for the evaluation module and the follow-up management module.

[0015] The present invention provides a pregnancy risk auxiliary management system based on cardiovascular disease. By specifically setting an assessment module that can assess the patient's pregnancy risk and a follow-up management module that can provide corresponding follow-up management suggestions based on the pregnancy risk assessment results, the auxiliary management system can automatically generate targeted pregnancy risk assessment results and follow-up management suggestions based on the patient's relevant basic data. This not only significantly improves the efficiency of physicians and pharmacists in assessing and managing the cardiovascular risks of patients receiving ART, greatly saving follow-up management time; it also significantly improves the accuracy, comprehensiveness and reliability of follow-up management suggestions, and helps to provide more timely and effective follow-up management suggestions for related risks of cardiovascular diseases during pregnancy. The system is suitable for large-scale application in pregnancy risk auxiliary management based on cardiovascular diseases.

[0016] Among them, preferably, the system management module includes a data backup and recovery submodule, a user authority setting submodule and a pregnancy data recording submodule; the user authority setting submodule is used to grant login permissions according to set values ​​(such as physician or pharmacist level); the data backup and recovery submodule is used to record data loss due to unexpected situations to ensure data integrity; the pregnancy data recording submodule is used to record data information related to the pregnancy process of each patient to facilitate data backup, organization and review.

[0017] Preferably, the information interaction module includes an input module and a receiving and display module; the input module is used to input relevant data; the receiving and display module is used to receive and display relevant data;

[0018] Among them, preferably, the physician information interaction module includes an obstetrician side, a cardiologist side and a pharmacist side; physicians can view, review and modify relevant data through the physician information interaction module.

[0019] Among them, preferably, the entry module includes an automatic import submodule and a custom entry module; the automatic import submodule is used to automatically import relevant information; the custom entry module is used for users to enter relevant information by themselves.

[0020] Preferably, the custom entry module includes an image recognition entry module and a manual entry module; the image recognition entry module refers to a functional module that can scan or take pictures, use OCR technology to automatically identify the text content in the picture and convert it into an editable text format, thereby realizing automatic entry; the manual entry module refers to a functional module that requires the user to enter information word by word through the keyboard to realize entry, and is suitable for scenarios that cannot be recognized by OCR or require high-precision proofreading.

[0021] Preferably, the manual entry module can also be used by the patient to manually correct data that cannot be recognized or is incorrectly recognized during the entry process of the image recognition module, especially to correct the units of the data.

[0022] Among them, preferably, the basic information includes the patient's name, age, ID number, previous medical history, previous medication history and drug allergy history; the symptoms and signs during pregnancy include gestational age data, diet information, exercise information and test results; the diagnosis and treatment plan includes medical advice and medication plan; the liver and kidney function level is evaluated based on clinical test data and patient basic information; specifically: the result is calculated using the creatinine clearance calculation formula, and the renal function level is judged according to the range of the result; the liver function level is judged using the Child-Pugh grading standard.

[0023] Preferably, the supporting database is used to store existing data information; existing data information such as: drug interaction data, liver and kidney function medication contraindications, medication contraindications during ART, medication contraindications during pregnancy and pregnancy lifestyle and dietary precautions.

[0024] The drug interaction information is a database that records the synergistic or antagonistic effects between two or more drugs when used simultaneously or sequentially. This effect may change the efficacy of the drugs or increase the risk of adverse reactions, and also includes pharmacokinetic characteristics data; such as the Lexicomp and Micromedex databases.

[0025] The liver and kidney function medication contraindications are a database that records the correspondence between liver and kidney function levels and relevant drug dosages, as well as related information such as medication contraindications, such as the MCDEX database.

[0026] The contraindications for medication during ART are related databases that record contraindications for medication during ART, such as Reprotox® and TERIS database (Teratogenic Risk Information System).

[0027] The pregnancy contraindications information is a database that records relevant information such as contraindications and dosage of medications during pregnancy, such as PLLR (Pregnancy and Lactation Labeling Rules).

[0028] The pregnancy lifestyle and dietary precautions are data that record relevant precautions and suggestions for pregnant women regarding life, diet, etc. during pregnancy. The data comes from the comprehensive recommendations of the Chinese Nutrition Society, the American College of Obstetricians and Gynecologists, and the World Health Organization.

[0029] Among them, the pregnancy risk assessment results include: high-risk pregnancy, moderate-risk pregnancy and low-risk pregnancy; high-risk pregnancy means that the incidence of cardiovascular events is >20%, the maternal mortality rate is significantly increased, or the maternal and fetal complications are severely increased; moderate-risk pregnancy means that the incidence of cardiovascular events is 6-10%, the maternal mortality rate is slightly increased, or the maternal and fetal complications are moderately increased; low-risk pregnancy means that the incidence of cardiovascular events is 2-5%, the maternal mortality rate is not significantly increased, or the maternal and fetal complications are not increased or are slightly increased.

[0030] Among them, preferably, the assessment module scores and grades the patient's relevant basic data based on the modified World Health Organization (mWHO) risk assessment standard, the ZAHARA score (cardiovascular risk prediction model during pregnancy) standard and the CARPREG score standard (congenital heart disease pregnancy risk assessment), and outputs a pregnancy risk assessment result according to the scoring and grading results; including: if the patient's mWHO risk grade is greater than or equal to grade III, the total ZAHARA score is greater than 2 points or the CARPREG score is greater than or equal to 1 point, then output a "high-risk pregnancy" pregnancy risk assessment result; if the patient's CARPREG score is less than 1 point, and the mWHO risk grade is grade II, or the total ZAHARA score is less than 2 and greater than 0.5 points, then output a "medium-risk pregnancy" pregnancy risk assessment result; if the patient's CARPREG score is less than 1 point, and the mWHO risk grade is grade I and the total ZAHARA score is less than or equal to 0.5 points, then output a "low-risk pregnancy" pregnancy risk assessment result.

[0031] Preferably, the assessment module outputs a recommendation on whether to perform ART based on the pregnancy risk assessment result; including: if the pregnancy risk assessment result is "high risk pregnancy", outputting a recommendation that "ART is not recommended to be continued"; if the pregnancy risk assessment result is "medium risk pregnancy and low risk pregnancy", outputting a recommendation that "ART can be continued".

[0032] Among them, preferably, the follow-up management module includes a treatment management suggestion submodule, a medication suggestion submodule and a lifestyle and diet suggestion submodule.

[0033] Preferably, the follow-up management recommendations include treatment management recommendations, medication recommendations, and lifestyle and dietary recommendations.

[0034] Preferably, the treatment management recommendation submodule outputs treatment management recommendations based on the patient's pregnancy risk assessment results; including: if the pregnancy risk assessment result is low risk, outputting the recommendation of "conducting 1-2 pregnancy risk assessments during pregnancy"; if the pregnancy risk assessment result is medium risk, outputting the recommendation of "conducting a pregnancy risk assessment at least once every 3 months during pregnancy"; if the assessment result is high risk, outputting the recommendation of "not recommending continuing the pregnancy or conducting a pregnancy risk assessment once a month".

[0035] Preferably, the treatment management recommendations also include treatment management recommendations for patients with specific cardiovascular diseases (including venous thromboembolism, hyperlipidemia, stroke, and essential hypertension) or cardiovascular high risk factors (ischemic heart disease symptoms), including:

[0036] If the patient has a history of venous thromboembolism after or without hormone exposure, the output is a recommendation to "start thromboprophylaxis at the start of ovarian gonadotropin stimulation"; if ovarian hyperstimulation syndrome occurs, the output is a recommendation to "start preventive anticoagulation therapy"; if the patient still develops venous thromboembolism during pregnancy after the above measures, the output is a recommendation to "start therapeutic anticoagulation";

[0037] If the patient has a history of hyperlipidemia, the output is "All hyperlipidemia medications can continue to be used during gamete retrieval (gamete (sperm and egg) retrieval is a key step in assisted reproductive technology, which refers to the safe and effective method of obtaining mature gametes for subsequent fertilization and embryo transfer). No special monitoring is required during assisted reproductive technology. During pregnancy, pay attention to monitoring for atherosclerotic cardiovascular disease (ASCVD) that may be caused by hyperlipidemia." If ASCVD occurs during pregnancy, the output is "Initiate ASCVD treatment."

[0038] If the patient has had a stroke before, the output is "the continuation or discontinuation of antiplatelet drugs should be determined based on the patient's individual risk"; if another stroke occurs during pregnancy, the output is "treatment should be initiated based on the patient's stroke condition";

[0039] If the patient has a history of essential hypertension, the output is a recommendation to "optimize blood pressure control to systolic blood pressure (SBP) below 130 mmHg and diastolic blood pressure (DBP) below 80 mmHg, and pay attention to monitoring for hypertensive disorders during pregnancy." If the systolic blood pressure during pregnancy is higher than 155 mmHg or the diastolic blood pressure is higher than 105 mmHg, the output is a recommendation to "initiate antihypertensive treatment";

[0040] If the patient has or develops symptoms of ischemic heart disease in the past, the system outputs a suggestion to "perform cardiovascular imaging examination first"; if the results of the cardiovascular imaging examination are abnormal, the system outputs a suggestion to "perform treatment first to ensure that there are no ischemic symptoms in the heart before performing assisted reproductive technology"; if symptoms of ischemic heart disease reappear during pregnancy, the system outputs a suggestion to "start treatment for ischemic heart disease"; the cardiovascular imaging examination includes stress echocardiography and echocardiography.

[0041] Preferably, the medication recommendation submodule outputs medication recommendations based on medication contraindications for liver and kidney function, drug interaction information, medication contraindications during ART, and medication contraindications during pregnancy; the medication recommendations include drug interaction risk recommendations and drug usage and dosage risk recommendations.

[0042] Preferably, the drug interaction risk recommendation is obtained by judging the clinical significance of drug interactions in the medication regimen based on drug interaction data, including: the drugs in the medication regimen are prohibited from being used in combination, otherwise the efficacy and safety of the drugs will be seriously affected; the risk of drug combination in the medication regimen is serious, and the combination should be used with caution when necessary, which will moderately affect the efficacy and safety of the drugs; the risk of drug combination in the medication regimen is moderate, and the drugs can be used in combination, which will slightly affect the efficacy and safety of the drugs; the risk of drug combination in the medication regimen is slight, and the drugs can be used in combination, which will not affect the efficacy and safety of the drugs; the risk of drug combination in the medication regimen is unknown, and there is currently insufficient evidence to determine the risk level of drug combination.

[0043] Preferably, the drug usage and dosage risk recommendation is obtained by judging the usage and dosage of drugs in the medication regimen based on the patient's basic information data, contraindications for liver and kidney function, contraindications for medication during ART and pregnancy (PLLR (pregnancy and lactation labeling rules), TERIS data (teratogenic risk information data)) and drug interaction data, including: the drug in the medication regimen is prohibited from use, resulting in an extremely high risk of fetal malformation; the drug dosage in the medication regimen has a drug treatment risk, the drug needs to be reduced, and a recommended dosage of the drug is given; the drug dosage in the medication regimen has a drug treatment risk, the drug needs to be increased, and a recommended dosage of the drug is given; there is no problem with the drug dosage in the medication regimen and no adjustment is required; more preferably, for easy distinction, the drug dosage risk recommendations can be marked with different colors, such as: red for drug contraindications, yellow for drug treatment risks that require a reduction, blue for drug treatment risks that require an increase, and green for no problem with drug dosage.

[0044] Preferably, the lifestyle and diet advice module outputs lifestyle and diet advice based on the symptom and sign data during pregnancy and the lifestyle and diet precautions during pregnancy.

[0045] In order to achieve the above-mentioned purpose of the invention, the present invention further provides a method for auxiliary management of pregnancy risks based on cardiovascular diseases, and the method for auxiliary management of pregnancy risks is implemented based on the above-mentioned auxiliary management system for pregnancy risks.

[0046] Preferably, the pregnancy risk auxiliary management method comprises the following steps:

[0047] (1) Enter the patient's relevant basic data into the pregnancy risk auxiliary management system through the patient information interaction module;

[0048] (2) Based on the input patient-related basic data, the assessment module assesses the pregnancy risk and outputs the pregnancy risk assessment results and recommendations on whether to continue ART;

[0049] (3) Receive and review the pregnancy risk assessment results and the recommendation on whether to continue ART output by the assessment module through the physician information interaction module, and then send the reviewed pregnancy risk assessment results and the recommendation on whether to continue ART to the patient information interaction module and the follow-up management module;

[0050] (4) The follow-up management module outputs follow-up management recommendations based on the pregnancy risk assessment results and patient-related basic data;

[0051] (5) The physician information interaction module receives and reviews the follow-up management suggestions output by the follow-up management module, and then sends the reviewed follow-up management suggestions to the patient information interaction module.

[0052] The present invention provides a method for auxiliary management of pregnancy risks based on cardiovascular disease. The method utilizes the function of the auxiliary management system of pregnancy risk to automatically assess the patient's pregnancy risk and provide follow-up management suggestions based on the patient's relevant basic data, which significantly improves the efficiency of physicians and pharmacists in assessing and managing the cardiovascular risks of patients undergoing ART, saving time for doctors and patients. At the same time, the management method of the present invention can not only timely prevent the risks related to cardiovascular diseases in patients, but also help to improve the success rate of ART in CVD patients; it can also reduce adverse pregnancy outcomes and reduce the pregnancy risk of CVD patients during the ART process, and is suitable for large-scale promotion and application.

[0053] Compared with the prior art, the present invention has the following beneficial effects:

[0054] 1. The pregnancy risk auxiliary management system of the present invention can conduct targeted assessments of patients' pregnancy risks and provide corresponding follow-up management recommendations, significantly improving the accuracy, comprehensiveness, and reliability of follow-up management recommendations. It helps to achieve more timely and effective follow-up management of patients' cardiovascular disease-related risks during pregnancy, and is suitable for large-scale application in pregnancy risk auxiliary management based on cardiovascular diseases.

[0055] 2. The pregnancy risk auxiliary management system of the present invention can automatically assess the patient's pregnancy risk and provide corresponding follow-up management recommendations based on the patient's relevant information data, significantly improving the efficiency of physicians and pharmacists in assessing and managing the cardiovascular risks of patients receiving ART, and greatly saving the time of doctors and patients.

[0056] 3. The pregnancy risk auxiliary management method of the present invention can effectively assist physicians in timely and effective prevention of cardiovascular disease-related risks in patients, help improve the success rate of ART in CVD patients and reduce the pregnancy risk of CVD patients during the ART process, thereby significantly reducing adverse pregnancy outcomes. It is suitable for large-scale application in the pregnancy risk auxiliary management of cardiovascular disease patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] Figure 1 This is a schematic diagram of the structure of the cardiovascular disease-based pregnancy risk auxiliary management system in Example 1 of the present invention;

[0058] Figure 2 This is a flow chart of the method for auxiliary management of pregnancy risks based on cardiovascular disease in Example 2 of the present invention. DETAILED DESCRIPTION

[0059] In order to more clearly describe the invention purpose, technical solutions and technical effect advantages in the specific implementation cases of the present invention, the following will be described in detail with reference to the solutions in the specific embodiments of the present invention. The specific technical solutions involved in the following specific embodiments are only for the purpose of clearly and completely describing the innovative technical solutions of the present invention. They themselves are only part of the specific implementation plans that can be adopted by the present invention, not all embodiments, and should not be understood as limiting the innovative solutions of the present invention. Any solution that adopts the same inventive concept of the present invention should be included in the scope of protection of the present invention.

[0060] For those skilled in the art, when understanding the solutions described in the specific embodiments of the present invention, they can refer to conventional technical manuals in the field. At the same time, for the places where the above-mentioned terms appear, they can make appropriate understanding or adjustments for reference, and deduce the implementation of the same or similar technical solutions without paying any creative work.

[0061] Example 1

[0062] A pregnancy risk auxiliary management system based on cardiovascular disease (structure as Figure 1 As shown in Figure 1), it mainly consists of system management module, evaluation module, follow-up management module, information interaction module and support database;

[0063] Among them, the system management module is used to assist in the basic maintenance and settings of the management system;

[0064] The system management module includes a data backup and recovery submodule, a user authority setting submodule, and a pregnancy data recording submodule; the user authority setting submodule is used to grant login permissions based on set values ​​(such as physician or pharmacist level); the data backup and recovery submodule is used to record data loss due to unexpected situations to ensure data integrity; the pregnancy data recording submodule is used to record data information related to each patient's pregnancy process to facilitate data backup, organization, and review.

[0065] The assessment module is used to assess the patient's pregnancy risk based on the patient-related basic data collected by the patient information interaction module, and output the pregnancy risk assessment results and recommendations on whether to continue ART;

[0066] The patient's relevant basic data includes at least one of basic information, liver and kidney function level, pregnancy symptoms and signs, and diagnosis and treatment plan; basic information includes the patient's name, age, ID number, previous medical history, previous medication history, and drug allergy history; symptoms and signs during pregnancy include gestational age data, diet information, exercise information, and test results; the diagnosis and treatment plan includes doctor's orders and medication plan; the liver and kidney function level is assessed based on clinical test data and the patient's basic information;

[0067] Pregnancy risk assessment results include: high-risk pregnancy, moderate-risk pregnancy, and low-risk pregnancy. If the patient's mWHO risk grade is greater than or equal to grade III, the total ZAHARA score is greater than 2, or the CARPREG score is greater than or equal to 1, the pregnancy risk assessment result is "high-risk pregnancy". If the patient's CARPREG score is less than 1, and the mWHO risk grade is grade II, or the total ZAHARA score is less than 2 and greater than 0.5, the pregnancy risk assessment result is "moderate-risk pregnancy". If the patient's CARPREG score is less than 1, and the mWHO risk grade is grade I, and the total ZAHARA score is less than or equal to 0.5, the pregnancy risk assessment result is "low-risk pregnancy".

[0068] The assessment module outputs a recommendation on whether to proceed with ART based on the pregnancy risk assessment results; including: if the pregnancy risk assessment result is "high risk pregnancy", the recommendation of "not recommending to continue with ART" is output; if the pregnancy risk assessment result is "medium risk pregnancy and low risk pregnancy", the recommendation of "can continue with ART" is output.

[0069] The follow-up management module is used to output follow-up management suggestions based on the patient's relevant basic data and pregnancy risk assessment results. The follow-up management module includes a treatment management suggestion submodule, a medication suggestion submodule, and a lifestyle and diet suggestion submodule. Follow-up management suggestions include treatment management suggestions, medication suggestions, and lifestyle and diet suggestions.

[0070] The treatment management recommendation submodule outputs treatment management recommendations based on the patient's pregnancy risk assessment results; including: if the pregnancy risk assessment result is low risk, the recommendation of "conducting 1-2 pregnancy risk assessments during pregnancy" is output; if the pregnancy risk assessment result is medium risk, the recommendation of "conducting a pregnancy risk assessment at least every 3 months during pregnancy" is output; if the assessment result is high risk, the recommendation of "not recommending continuing the pregnancy or conducting a pregnancy risk assessment every month" is output.

[0071] The medication recommendation submodule outputs medication recommendations based on medication contraindications for liver and kidney function, drug interaction information, medication contraindications during ART, and medication contraindications during pregnancy. Medication recommendations include drug interaction risk recommendations and drug usage and dosage risk recommendations.

[0072] Drug interaction risk recommendations are based on the clinical significance of drug interactions in the medication regimen based on drug interaction data, including: the drugs in the medication regimen are prohibited from being used in combination, otherwise the efficacy and safety of the drugs will be seriously affected; the risk of drug combination in the medication regimen is serious, and the combination should be used with caution when necessary, and the efficacy and safety of the drugs will be moderately affected; the risk of drug combination in the medication regimen is moderate, and the drug combination can be used, but the efficacy and safety of the drugs will be slightly affected; the risk of drug combination in the medication regimen is slight, and the drug combination can be used, and the efficacy and safety of the drugs will not be affected; the risk of drug combination in the medication regimen is unknown, and there is currently insufficient evidence to determine the risk level of drug combination;

[0073] The risk recommendations for drug usage and dosage are based on the patient's basic information data, contraindications for liver and kidney function, contraindications for drug use during ART and pregnancy (PLLR (pregnancy and lactation labeling rules), TERIS data (teratogenic risk information data)) and drug interaction data to determine the usage and dosage of drugs in the medication regimen, including: the drug in the medication regimen is prohibited, resulting in an extremely high risk of fetal malformation; there is a drug treatment risk in the dosage of the drug in the medication regimen, the drug needs to be reduced, and a recommended dosage of the drug is given; there is a drug treatment risk in the dosage of the drug in the medication regimen, the drug needs to be increased, and a recommended dosage of the drug is given; there is no problem with the dosage of the drug in the medication regimen and no adjustment is required.

[0074] The lifestyle and diet advice module outputs lifestyle and diet advice based on the symptom and sign data during pregnancy and the lifestyle and diet precautions during pregnancy.

[0075] Among them, the information interaction module includes a patient information interaction module and a physician information interaction module;

[0076] The information interaction module includes an input module and a receiving and display module; the input module is used to input relevant data; the receiving and display module is used to receive and display relevant data;

[0077] The patient information interaction module is used to input patient-related basic data and receive the pregnancy risk assessment results output by the assessment module, the recommendation on whether to continue ART, and the follow-up management recommendations output by the follow-up management module;

[0078] The physician information interaction module is used to receive and review the pregnancy risk assessment results output by the assessment module, the recommendation on whether to continue ART, and the follow-up management recommendations output by the follow-up management module.

[0079] Among them, the support database is used to provide data support for the evaluation module and follow-up management module, including: drug interaction data, contraindications for liver and kidney function medication, contraindications for medication during ART, contraindications for medication during pregnancy, and dietary precautions during pregnancy.

[0080] In the preferred embodiment, the entry module includes an automatic import submodule and a custom entry module; the automatic import submodule is used to automatically import patient-related information; the custom entry module is used for users to enter patient-related information by themselves.

[0081] In the preferred embodiment, the custom entry module includes an image recognition entry module and a manual entry module; the image recognition entry module refers to a functional module that can scan or take pictures, use OCR technology to automatically identify the text content in the picture and convert it into an editable text format, thereby realizing automatic entry; the manual entry module refers to a functional module that requires the user to enter information word by word through the keyboard to realize entry, which is suitable for scenarios that cannot be recognized by OCR or require high-precision proofreading.

[0082] In a preferred embodiment, the manual entry module can also be used by the patient to manually correct data that cannot be recognized or is incorrectly recognized during the entry process of the image recognition module, especially to correct the units of the data.

[0083] In the preferred solution, the physician information interaction module includes an obstetrician side, a cardiologist side, and a pharmacist side; physicians can view and review patient-related data through the physician information interaction module.

[0084] In the preferred embodiment, the creatinine clearance calculation formula is used to calculate the result, and the renal function level is judged according to the range of the result; the Child-Pugh grading standard is used to judge the liver function level.

[0085] In preferred embodiments, treatment management recommendations also include treatment management recommendations for patients with specific cardiovascular diseases or cardiovascular risk factors, including:

[0086] If the patient has a history of venous thromboembolism after or without hormone exposure, the output is a recommendation to "start thromboprophylaxis at the start of ovarian gonadotropin stimulation"; if ovarian hyperstimulation syndrome occurs, the output is a recommendation to "start preventive anticoagulation therapy"; if the patient still develops venous thromboembolism during pregnancy after the above measures, the output is a recommendation to "start therapeutic anticoagulation";

[0087] If the patient has a history of hyperlipidemia, the output is the recommendation that "all hyperlipidemia medications can continue to be used during gamete retrieval, no special monitoring is required during assisted reproductive technology, and attention should be paid to monitoring for atherosclerotic cardiovascular disease (ASCVD) that may be caused by hyperlipidemia during pregnancy." If ASCVD occurs during pregnancy, the output is the recommendation to "initiate ASCVD treatment";

[0088] If the patient has had a stroke before, the output is "the continuation or discontinuation of antiplatelet drugs should be determined based on the patient's individual risk"; if another stroke occurs during pregnancy, the output is "treatment should be initiated based on the patient's stroke condition";

[0089] If the patient has a history of essential hypertension, the output is a recommendation to "optimize blood pressure control to systolic blood pressure (SBP) below 130 mmHg and diastolic blood pressure (DBP) below 80 mmHg, and pay attention to monitoring for hypertensive disorders during pregnancy." If the systolic blood pressure during pregnancy is higher than 155 mmHg or the diastolic blood pressure is higher than 105 mmHg, the output is a recommendation to "initiate antihypertensive treatment";

[0090] If the patient has or develops symptoms of ischemic heart disease in the past, the system outputs a suggestion to "perform cardiovascular imaging examination first"; if the results of the cardiovascular imaging examination are abnormal, the system outputs a suggestion to "perform treatment first to ensure that there are no ischemic symptoms in the heart before performing assisted reproductive technology"; if symptoms of ischemic heart disease reappear during pregnancy, the system outputs a suggestion to "start treatment for ischemic heart disease"; the cardiovascular imaging examination includes stress echocardiography and echocardiography.

[0091] In the preferred solution, for easy distinction, drug dosage risk recommendations can be marked with different colors, such as: red indicates that the drug is contraindicated, yellow indicates that the dosage needs to be reduced due to the risk of drug treatment, blue indicates that the dosage needs to be increased due to the risk of drug treatment, and green indicates that there is no problem with the drug dosage.

[0092] The pregnancy risk auxiliary management system of the present invention can automatically generate targeted pregnancy risk assessment results and follow-up management recommendations based on the patient's relevant basic data. It can not only significantly improve the efficiency of physicians and pharmacists in assessing and managing the cardiovascular risks of patients undergoing ART, greatly saving follow-up management time; it can also significantly improve the accuracy, comprehensiveness and reliability of follow-up management recommendations, and help provide more timely and effective follow-up management recommendations for related cardiovascular disease risks during pregnancy.

[0093] Example 2

[0094] A method for assisting management of pregnancy risk based on cardiovascular disease (process such as Figure 2 As shown), it is implemented based on the pregnancy risk auxiliary management system in Example 1;

[0095] The specific steps include:

[0096] (1) Enter the patient's relevant basic data into the pregnancy risk auxiliary management system through the patient information interaction module;

[0097] (2) Based on the input patient-related basic data, the assessment module assesses the pregnancy risk and outputs the pregnancy risk assessment results and recommendations on whether to continue ART;

[0098] (3) Receive and review the pregnancy risk assessment results and the recommendation on whether to continue ART output by the assessment module through the physician information interaction module, and then send the reviewed pregnancy risk assessment results and the recommendation on whether to continue ART to the patient information interaction module and the follow-up management module;

[0099] (4) The follow-up management module outputs follow-up management recommendations based on the pregnancy risk assessment results and patient-related basic data;

[0100] (5) The physician information interaction module receives and reviews the follow-up management suggestions output by the follow-up management module, and then sends the reviewed follow-up management suggestions to the patient information interaction module.

[0101] The pregnancy risk auxiliary management method of the present invention significantly improves the efficiency of physicians and pharmacists in assessing and managing cardiovascular risks in patients undergoing ART, saving time for physicians and patients. At the same time, it can also provide timely prevention of cardiovascular disease-related risks in patients, helping to improve the success rate of ART in CVD patients, reduce adverse pregnancy outcomes, and lower the pregnancy risk of CVD patients during the ART process.

[0102] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A method for assisting management of pregnancy risks based on cardiovascular disease, characterized in that: The method is implemented based on a pregnancy risk auxiliary management system for cardiovascular diseases, which includes a system management module, an evaluation module, a follow-up management module, an information interaction module, and a support database; management methods; The management method comprises the following steps: (1) Enter the patient's relevant basic data into the pregnancy risk auxiliary management system through the patient information interaction module; (2) Based on the input patient-related basic data, the assessment module assesses the pregnancy risk and outputs the pregnancy risk assessment results and recommendations on whether to continue ART; (3) receiving and reviewing the pregnancy risk assessment results and the recommendation on whether to continue ART output by the assessment module through the physician information interaction module, and then sending the reviewed pregnancy risk assessment results and the recommendation on whether to continue ART to the patient information interaction module and the follow-up management module; (4) The follow-up management module outputs follow-up management recommendations based on the pregnancy risk assessment results and patient-related basic data; (5) receiving and reviewing the follow-up management suggestions output by the follow-up management module through the physician information interaction module, and then sending the reviewed follow-up management suggestions to the patient information interaction module; Wherein, the system management module is used to assist in the basic maintenance and setting of the management system; The evaluation module is used to score and grade the patient-related basic data collected by the patient information interaction module based on the mWHO risk assessment standard, the ZAHARA scoring standard and the CARPREG scoring standard. If the patient's mWHO risk grade is greater than or equal to III, the total ZAHARA score is greater than 2, or the CARPREG score is greater than or equal to 1, the pregnancy risk assessment result of "high pregnancy risk" will be output, and a recommendation not to perform ART will be output; If the patient's CARPREG score is less than 1, and the mWHO risk classification is II, or the total ZAHARA score is less than 2 and greater than 0.5, the pregnancy risk assessment result of "moderate risk" is output, and a recommendation for ART is output; If the patient's CARPREG score is less than 1, the mWHO risk classification is I, and the total ZAHARA score is less than or equal to 0.5, the pregnancy risk assessment result of "low pregnancy risk" is output, and a recommendation for ART is output; The patient-related basic data includes at least one of basic information, liver and kidney function level, pregnancy symptoms and signs, and diagnosis and treatment plan; The follow-up management module is used to output follow-up management suggestions based on the patient's relevant basic data and pregnancy risk assessment results; the follow-up management module includes a treatment management suggestion submodule, a medication suggestion submodule and a lifestyle and diet suggestion submodule; the follow-up management suggestions include treatment management suggestions, medication suggestions and lifestyle and diet suggestions; the medication suggestions include drug interaction risk suggestions and drug usage and dosage risk suggestions; The treatment management recommendation submodule outputs treatment management recommendations based on the patient's pregnancy risk assessment results. These recommendations include: if the pregnancy risk assessment result indicates low risk, a recommendation to conduct one to two pregnancy risk assessments during pregnancy is output; if the pregnancy risk assessment result indicates moderate risk, a recommendation to conduct a pregnancy risk assessment at least every three months during pregnancy is output; and if the assessment result indicates high risk, a recommendation to not continue the pregnancy or to conduct a pregnancy risk assessment every month is output. The information interaction module includes a patient information interaction module and a physician information interaction module; the patient information interaction module is used to input patient-related basic data and receive the pregnancy risk assessment results output by the assessment module, including recommendations on whether to continue ART, and follow-up management recommendations output by the follow-up management module; The physician information interaction module is used to receive and review the pregnancy risk assessment results output by the assessment module, the recommendation on whether to continue ART, and the follow-up management recommendations output by the follow-up management module; The support database is used to provide data support for the evaluation module and the follow-up management module; The supporting databases include a drug interaction database, a liver and kidney function medication contraindication database, an ART medication contraindication database, a pregnancy medication contraindication database, and pregnancy lifestyle and dietary precautions.

2. The method for assisting management of pregnancy risks based on cardiovascular disease according to claim 1, characterized in that: The system management module includes a data backup and recovery submodule, a user authority setting submodule and a pregnancy data recording submodule.

3. The method for assisting management of pregnancy risks based on cardiovascular disease according to claim 1, characterized in that: The basic information includes the patient's name, age, ID number, previous medical history, previous medication history and drug allergy history; the symptoms and signs during pregnancy include gestational age data, diet information, exercise information and test results; the diagnosis and treatment plan includes medical advice and medication plan; the liver and kidney function level is assessed based on clinical test data and the patient's basic information.

4. The method for assisting management of pregnancy risks based on cardiovascular disease according to claim 1, characterized in that: The drug interaction risk recommendations are based on the clinical significance of drug interactions in the medication regimen based on drug interaction data, including: the drugs in the medication regimen are prohibited from being used in combination, otherwise the efficacy and safety of the drugs will be seriously affected; the risk of drug combination in the medication regimen is serious, and they should be used in combination with caution when necessary, which will moderately affect the efficacy and safety of the drugs; the risk of drug combination in the medication regimen is moderate, and they can be used in combination, which will slightly affect the efficacy and safety of the drugs; the risk of drug combination in the medication regimen is slight, and they can be used in combination, which will not affect the efficacy and safety of the drugs; the risk of drug combination in the medication regimen is unknown, and there is currently insufficient evidence to determine the risk level of drug combination.

5. The method for assisting management of pregnancy risks based on cardiovascular disease according to claim 1, characterized in that: The drug usage and dosage risk recommendations are based on the patient's basic information data, contraindications for liver and kidney function, contraindications for medication during ART and pregnancy, and drug interaction data to judge the usage and dosage of drugs in the medication regimen, including: the drugs in the medication regimen are prohibited from use, resulting in an extremely high risk of fetal malformation; the drug dosage in the medication regimen poses a drug treatment risk, the drug needs to be reduced, and a recommended drug dosage is given; the drug dosage in the medication regimen poses a drug treatment risk, the drug needs to be increased, and a recommended drug dosage is given; there is no problem with the drug dosage in the medication regimen and no adjustment is required.

6. The method for assisting management of pregnancy risks based on cardiovascular disease according to claim 1, characterized in that: The drug interaction database includes the Lexicomp database and the Micromedex database.

7. The method for assisting management of pregnancy risks based on cardiovascular disease according to claim 1, characterized in that: The liver and kidney function medication contraindication database is the MCDEX database.

8. The method for assisting management of pregnancy risks based on cardiovascular disease according to claim 1, characterized in that: The database of contraindications for medication during ART includes the Reprotox® database and the TERIS database.

9. The method for assisting management of pregnancy risks based on cardiovascular disease according to claim 1, characterized in that: The database of contraindications for medication during pregnancy is a database of labeling rules for pregnancy and lactation.

Images